Company / Current Liabilities
Tarsus Pharmaceuticals, Inc. Current Liabilities History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$135.7M
FY2025
5-year range
$11.5M / $135.7M
FY2021-FY2025
Trend
+68.3%
vs FY2024
Sector context
#80 of 213
Health Care
What the data says
At $136M, Tarsus Pharmaceuticals, Inc.'s current liabilities ranks #134 of 213 in the Health Care sector. Current Liabilities has increased for 6 consecutive years, from $819,000 in FY2019 to $136M in FY2025.
Based on SEC 10-K filings.
$136M in FY2025 with a 5-year CAGR of +90.7%.
Increased from $37M to $136M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +106.4%
- 5-Year CAGR
- +90.7%
- 10-Year CAGR
- -
Sector benchmark
#134 of 213 in Health CareTop 62% of 213This company $135.7M Sector average $1.6B
▼
-91.5% below sector average
Key checks
Key Insights
- Tarsus Pharmaceuticals, Inc.'s current liabilities has grown for 6 consecutive years.
- 5-year CAGR of +90.7%, indicating consistent growth.
- In FY2025, current liabilities increased 68.3% year-over-year.
- Ranks #80 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $135.7M | +68.3% |
| FY2024 | $80.6M | +118.2% |
| FY2023 | $36.9M | +139.4% |
| FY2022 | $15.4M | +34.4% |
| FY2021 | $11.5M | +113.1% |
| FY2020 | $5.4M | +557.8% |
| FY2019 | $819.0K | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026